Results On timolol monotherapy patients with exfoliation glaucoma had a higher mean lOP
Exfoliation glaucoma patients have been shown previously to present with higher mean intraocular pressures (lOPs) in general and to have lOPs that are more difficult to control than primary open-angle glaucoma patients.1 In addition to the higher mean lOPs in exfoliation glaucoma, it has been shown recently that the peak and range of the lOPs throughout the day are greater than in primary open-angle glaucoma? Also, recent evidence has indicated that a higher mean, range and peak lOP continue to differentiate exfoliation glaucoma and primary open-angle glaucoma despite treatment with monotherapy using timolol maleate solution?
Because of the difficulty in controlling the lOP with a single agent in exfoliation glaucoma, it becomes important to assess carefully medicines which could be used as adjunctive therapy. Medicines that would be particularly effective in exfoliation glaucoma potentially could be a great benefit in preventing glaucomatous visual loss in these patients by minimising the lOP differences compared with primary open-angle glaucoma.
In the current study we investigated the adjunctive use of dorzolamide 2% used twice daily in conjunction with timolol maleate 0.5% solution used twice daily in both exfoliation glaucoma and primary open-angle glaucoma patients.
Materials and methods
We entered into this prospective study 62 consecutive Greek patients with either exfoliation glaucoma (31) or primary open- angle glaucoma (31) in whom monotherapy with timolol maleate 0.5% twice daily was not adequate in controlling their toP.
All patients treated with timolol maleate 0.5% b.i.d. whose lOP was greater than 21 mmHg at 08:00 hours met the criteria for inclusion in the present study. Patients with a history of ocular surgery/trauma, contact lens use, corneal abnormality, or any condition that prevented reliable applanation tonometry, were excluded. Similarly all patients with evidence of ocular infection, inflammation, or a history of renal or hepatic impairment were excluded from this study. In patients with bilateral glaucoma one eye was randomly selected to be included in this study. Patients were diagnosed and followed at the Glaucoma Unit of the University Department of Ophthalmology, AHEP A Hospital, Thessaloniki, Greece. Eligible glaucoma patients were recruited and the study was conducted between July 1996 and September 1997.
Eighteen patients were excluded from the study altogether. Fifteen were excluded because they demonstrated a well-controlled lOP on timolol alone or were too young or old and were disallowed for the purpose of matching. Patients were matched by age (::I:: 2 years) to eliminate any effect of a potentially older age population on lOP in the exfoliation glaucoma group.z· 3 Two additional patients declined due to the inconvenience of hospitalisation and one other patient could not be admitted for the last phasing due to another unrelated medical condition.
The methods for this study were similar to those described previously.z· 3 All 62 patients in the present study were treated with timolol maleate 0.5% solution (Merck Sharp & Dohme/Vianex, Athens) twice daily with the dosing regimen set at 08:00 and 20:00 hours. The signing of an institutional review board informed consent was not required. Patients were admitted to the hospital for the baseline 24 h lOP diurnal curve on timolol maleate after at least 3 months of chronic dosing. Pressure measurements were performed by the same investigators (A.M., T.B.), using the same instrument (Goldmann applanation tonometer). Patients were admitted in the morning and measurements were recorded at 10:00, 14:00, 18:00, 22:00, 02:00 and 06:00 hours. At the 22:00 hour measurement patients were awake at bed rest. The 06:00 hour lOP measurement was performed immediately after waking. Patients were encouraged to lead as normal a life as possible within the hospital boundaries.
Following discharge from the hospital patients who met the inclusion criteria for this study and whose lOP was not controlled sufficiently (i.e. lOP> 21 mmHg at 08:00 hours on timolol maleate alone) were started on dorzolamide 2% drops (Merck Sharp & Dohme/Vianex, Athens) twice daily. The dosing regimen of dorzolamide was set at 08:00 and 20:00 hours. Patients were instructed regarding study medication instillation and compliance. Dorzolamide drops were instilled approximately 10 min after timolol maleate drops. Patients who could not comply were excluded. All 62 patients who completed the dosing regimen were readmitted 2 months after their first diurnal curve with timolol for a second 24 h phasing while using dorzolamide and timolol maleate drops. Follow-up visits and appropriate treatment steps were scheduled according to the result of the diurnal curve. Statistical analysis was performed after patients with these two glaucomas were matched for age and sex (Table 1) . Statistical analyses on the lOP at each time point were evaluated by an unpaired t-test between diagnostic groupS.4 A paired t-test was used to evaluate the reduction in lOP from baseline within groups after the addition of dorzolamide. This study had an 80% power to detect a 1.7 mmHg difference in the lOP following the addition of dorzolamide as adjunctive therapy. A standard deviation of 3.2 mmHg was used. 5 • 6 An F-test was used to evaluate differences in the standard deviations between groups at each time point. 4 The significance level was set at 5% and all tests were a two-way analysis. Differences in visual acuity and cup to-disc ratio between groups were analysed by a Mann Whitney U-test? Differences in mean defect between groups were evaluated with an unpaired t-test.
Results

Patients
Sixty-two patients (31 with exfoliation glaucoma and 31 with primary open-angle glaucoma) were included in this trial. Baseline patient data are shown in Table 1 : age, gender, visual acuity, cup-to-disc ratio and visual field mean defect. No statistical difference between groups was noted for any parameter. All patients were ethnic Greek and Caucasian. Table 2 . A significant difference existed at each time point except at 18:00 hours between exfoliation glaucoma and primary open-angle glaucoma patients for the lOP (p < 0.05). Likewise, a significant difference in the maximum and minimum lOP as well as the standard deviation of the pressure at each time point existed between groups (p < 0.05). Table 3 shows the lOP results of both groups after dorzolamide was added to timolol maleate. A significant difference in lOP between groups remained at each time point except at 02:00 and 06:00 hours. A significant difference in the average maximum pressure still existed between groups but not for the minimum pressure. In addition, following the addition of dorzolamide only the daytime hours of 06:00, 10:00 and 14:00 hours showed a significant difference in the standard deviation of the lOP between groups. Table 4 shows the percentage and absolute reductions in lOP in patients on timolol maleate only compared with treatment with timolol maleate and dorzolamide together. A statistically significant reduction from baseline was shown at each time point for both exfoliation glaucoma and primary open-angle glaucoma patients (p < 0.05). The percentage reduction was not different between groups, however, at each time point (p > 0.05). However, the absolute reduction was significantly greater in exfoliation glaucoma patients (p < 0.05) in the early morning hours (02:00 and 06:00).
Safety
Two of 62 patients (3%) developed a moderate ocular intolerance to dorzolamide over the 2 months of therapy but tolerated the medication sufficiently to complete the second diurnal curve. Another patient who developed marked ocular intolerance 2 weeks after initiation of dorzolamide was discontinued from the study and is not included in the data reported here. Accordingly, the overall ocular incidence of intolerance was 3 of 63 patients (5%). Nineteen of 62 (30%) patients reported a bitter taste after instillation. Three patients (5%) experienced ocular side-effects (temporary blurring of vision in 1 patient and burning/ stinging or dryness after administration in 2 patients). These unsolicited symptoms did not affect the investigation but resulted in discontinuation of the medication in one of these patients after completion of the study. Non-ocular side-effects were not reported during the course of this investigation.
Discussion
Dorzolamide 2% is a topical carbonic anhydrase inhibitor which reduces the lOP by suppressing aqueous formation reduction.8 Wang and associates8 showed that aqueous production is reduced by between 13% and 18% by dorzolamide as monotherapy and by 24% when dorzolamide is added to timolol maleate; there is no apparent influence on outflow facility.8-1 3 Dorzolamide is most effective as a single agent given in the 2% concentration t.i.d.14 As monotherapy, dorzolamide has been reported to reduce the lOP from baseline by 10-26%.14-18 The peak lOP reduction from baseline appears to be between 17% and 24% and the trough effect between 13% and 18%? Strahlman and co-workers18 found that the efficacy of dorzolamide was slightly, but statistically less, than that of timolol maleate. In their study, dorzolamide tended to be more effective than betaxolol both at peak and trough levels.ls However, these differences were not statistically significant. As adjunctive therapy Nardin et al. 19 and Strahlman and associatesZO found that dorzolamide given twice daily may provide a peak response of an additional 13-20% reduction in the lOP when added to timolol maleate. Heijl and co-workersz1 showed in exfoliation glaucoma patients that as monotherapy timolol maleate was more effective in lowering the lOP than dorzolamide (29% vs 24%). Additionally, dorzolamide had about 15% additivity to timolol maleate both at daytime peak and trough levels?l However, previous work with exfoliation glaucoma patients frequently demonstrates a peak lOP outside normal office hours.z, 3 Additionally, few data compare the effect of dorzolamide in exfoliation glaucoma patients and primary open-angle glaucoma patients.
The purpose of this study was to investigate the efficacy of dorzolamide added to timolol maleate solution 0.5% given twice a day in patients with primary open-angle glaucoma or exfoliation glaucoma.
This study found that while using timolol maleate only, exfoliation glaucoma patients had higher baseline lOPs than primary open-angle glaucoma patients. Differences were observed between groups in mean lOPs at each time point throughout the day as well as between the average maximum and minimum lOPs across all patients. Also, on timolol maleate treatment only, the standard deviations of the lOPs at each time point were statistically higher in exfoliation glaucoma compared with primary open-angle glaucoma. These findings were consistent with past diurnal curve data comparing timolol maleate in exfoliation and primary open-angle glaucoma patients according to Topper and Brubaker?Z Following treatment with dorzolamide, differences in lOP between groups for most of the parameters discussed above remained. A statistical difference between groups in mean lOP still was observed at the 10:00,14:00, 18:00 and 22:00 hour time points, as well as in the average maximum lOP. Likewise, standard deviations between groups remained statistically different at 06:00, 10:00 and 14:00 hours. The percentage decrease in lOP was similar between groups from baseline following adjunctive treatment with dorzolamide at each time point. However, the absolute reduction in lOP was greater in the exfoliation glaucoma group during the early morning hours (02:00 and 06:00). The reason for this is not entirely clear from our results.
Safety following the addition of dorzolamide to timolol maleate was similar between exfoliation glaucoma and primary open-angle glaucoma groups and the incidence and types of side-effects were consistent with past studies? 3 Three patients experienced ocular intolerance, one of whom was discontinued from the study prior to the diurnal curve with dorzolamide. Two of these patients continued in the study despite the intolerance. Bitter taste, blurred vision, stinging and burning also were noted. One patient discontinued dorzolamide following the completion of the second diurnal curve because of ocular intolerance. No systemic side-effects were noted during the study.
This study suggests that dorzolamide as adjunctive therapy is equally effective in lowering the lOP in patients with exfoliation glaucoma as in those with primary open-angle glaucoma. However, it does little to change the basic lOP characteristics which distinguish exfoliation glaucoma from primary open-angle glaucoma.
Further study is needed to determine the best treatment regimen for exfoliation syndrome as well as to find lOP levels which are safe for these patients over a long period of time. Likewise, determining other factors besides the lOP which are associated with visual loss in exfoliation glaucoma may be important in preserving these patients' vision.
